Status:
WITHDRAWN
Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis
Lead Sponsor:
NImmune Biopharma
Conditions:
Eosinophilic Esophagitis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The proposed Phase 1b study design was a randomized, placebo-controlled, double-blind, study to evaluate the safety and pharmacokinetics of oral BT-11 in active eosinophilic esophagitis.
Eligibility Criteria
Inclusion
- No patients enrolled
Exclusion
Key Trial Info
Start Date :
January 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04835168
Start Date
January 30 2022
End Date
June 30 2022
Last Update
June 7 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.